Keefe, Bruyette & Woods upgraded shares of HIVE Blockchain Technologies (CVE:HIV – Free Report) to a moderate buy rating in a research note released on Wednesday,Zacks.com reports.
A number of other research analysts have also commented on HIV. Northland Capmk raised HIVE Blockchain Technologies to a “strong-buy” rating in a report on Thursday, September 19th. Cantor Fitzgerald upgraded HIVE Blockchain Technologies to a “strong-buy” rating in a report on Tuesday, October 29th. Finally, Roth Capital raised shares of HIVE Blockchain Technologies to a “strong-buy” rating in a research report on Wednesday, December 18th. Four research analysts have rated the stock with a strong buy rating, According to MarketBeat.com, the company has a consensus rating of “Strong Buy”.
View Our Latest Research Report on HIV
HIVE Blockchain Technologies Price Performance
Featured Articles
- Five stocks we like better than HIVE Blockchain Technologies
- Stock Splits, Do They Really Impact Investors?
- MercadoLibre: Latin America’s Digital Titan Just Got Cheaper
- Roth IRA Calculator: Calculate Your Potential Returns
- Breaking Down Pegasystems, A Wedbush Top AI Pick for 2025
- What is the Hang Seng index?
- Shutterstock and Getty: A $3.7 Billion Visual Content Giant
Receive News & Ratings for HIVE Blockchain Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HIVE Blockchain Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
